Harold Bernstein, R&D President and Chief Medical Officer of Maze Therapeutics, executed a significant sale of 15,000 shares on April 1, 2026, totaling approximately $442,000. This transaction, disclosed in a SEC Form 4 filing, involved the complete liquidation of his direct Common Stock holdings, although he retains substantial exposure through 237,407 stock options.
This sale is noteworthy for investors as it reflects Bernstein’s adherence to a Rule 10b5-1 trading plan, designed to mitigate insider trading risks. The timing coincides with a decline in Maze Therapeutics’ stock price, which peaked at $53.65 in March following positive clinical trial data but has since faced downward pressure as investors took profits. The company, still in the clinical stage and without revenue, reported a net loss of $131.1 million at the end of 2025.
For market professionals, Bernstein’s complete divestiture may not signal alarm, but it underscores the importance of evaluating the company’s pipeline, particularly the lead asset MZE829, as investors weigh the risks associated with potential regulatory approval against the backdrop of recent stock volatility.
Source: fool.com